COOPER COMPANIES, INC.
Close on Oct 19, 2026
- Market cap
- $11.25B
- P/E (TTM)
- 19.8
- Dividend yield
- –
About Cooper Companies
Ophthalmic Goods, SIC 3851
The Cooper Companies, Inc. is a global medical device company operating primarily through two business segments: CooperVision and CooperSurgical. CooperVision develops, manufactures, and markets a broad range of contact lenses, including spherical, toric, multifocal, and silicone hydrogel products. CooperSurgical focuses on healthcare solutions centered on women's health, fertility, and diagnostics, offering medical devices, surgical equipment, and specialized fertility technologies. The company serves healthcare professionals, fertility clinics, medical practices, hospitals, and consumers across vision care and surgical markets worldwide.
The company maintains extensive international operations spanning the United States, Europe, and other global regions. It conducts research, development, manufacturing, and distribution activities through facilities across multiple countries to support its commercial presence. The principal executive offices and corporate headquarters are located in San Ramon, California.
Summary of the business section of Cooper Companies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- COOPER COMPANIES, INC.
- Founded
- 1958
- Headquarters
- San Ramon, CA
- Address
- 6101 Bollinger Canyon Road, Suite 500 94583
- Phone
- (925) 460-3600
- Website
- www.coopercos.com
- Employees
- 500, Oct 31, 2025
- Industry
- Ophthalmic Goods
- Incorporated in
- Delaware
- Fiscal year ends
- October 31
- Auditor
- KPMG LLP, San Francisco, CA
Stock & identifiers
- Ticker
- COO
- Exchange
- Nasdaq
- IPO date
- Jan 21, 1983
- Shares outstanding
- 190M, Sep 3, 2026
- Public float
- $16.20B, Apr 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 4-for-1, Feb 20, 2024; 4-for-1, Feb 16, 2024; 2-for-1, Nov 25, 2002; 1-for-3 reverse, Sep 22, 1995
- SEC CIK
- 711404
- CUSIP
- 216648501
- ISIN
- US2166485019
- LEI
- QJKMVPIGLH7530PCUE20
- EIN
- 94-2657368
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Albert G. White III | President & CEO, Director | 254,491 |
| Brian G. Andrews | EVP, CFO & Treasurer | 30,728 |
| Gerard H. Warner III | President, CooperVision, Inc. | 20,971 |
| Holly R. Sheffield | President, CSI | 48,516 |
| Daniel G. McBride | EVP & Chief Operating Officer | 165,967 |
| Agostino Ricupati | SVP & CAO | 8,020 |
| Nicholas Khadder | VP, General Counsel & Corp Sec | 3,790 |
| Lawrence Erik Kurzius | Director | 31,099 |
| Paul A. Keel | Director | 4,701 |
| Walter M. Rosebrough Jr | Director | 20,832 |
| Barbara Carbone | Director | 3,050 |
| Robert S. Weiss | Director | 550,459 |
| Colleen Jay | Director | 39,907 |
| Maria Rivas | Director | 14,463 |
| Teresa S. Madden | Director | 15,679 |
| Cynthia L. Lucchese | Director | 12,767 |
| William A. Kozy | Director | 31,149 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. White | $16.05M | $1.77M | $4.12M | $67 | $104 |
| FY2024 Mr. White | $15.43M | $39.83M | $3.77M | $100 | $98 |
| FY2023 Mr. White | $13.49M | $22.31M | $3.46M | $75 | $75 |
| FY2022 Mr. White | $11.74M | -$9.23M | $3.12M | $66 | $77 |
| FY2021 Mr. White | $10.99M | $36.21M | $2.77M | $100 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“The Company employs approximately 500 people in research and development.”
Corporate history
Events identified from SEC filings